Scientists test drug safety in people with liver damage
NCT ID NCT07198087
Summary
This early-stage study aims to understand how a drug called tirabrutinib, used for a type of brain lymphoma, is processed by the body in people with different levels of liver damage. It will compare 32 participants—some with mild, moderate, or severe liver impairment and some healthy—to see how their livers handle the drug and check for safety. The goal is to gather knowledge to help doctors safely dose this medication for future patients with liver problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center, Inc.
RECRUITINGOrlando, Florida, 32809, United States
-
Panax Clinical Research
RECRUITINGMiami Lakes, Florida, 33014, United States
Conditions
Explore the condition pages connected to this study.